Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas
Objective:
The aim of this study was to determine whether adjuvant chemotherapy (AC) provides a survival benefit in patients with nonmetastatic poorly differentiated colorectal neuroendocrine carcinomas (CRNECs) following resection.
Background:
There is little evidence to support the association between use of AC and improved overall survival (OS) in patients with CRNECs.
Methods:
Patients with resected non-metastatic CRNECs were identified in the National Cancer Database (2004–2014). Inverse probability of treatment weighting (IPTW) method was used to reduce the selection bias. IPTW-adjusted Kaplan-Meier curves and Cox proportional hazards models were used to compare OS of patients in different treatment groups.
Results:
A total of 806 patients diagnosed between 2004 and 2014 met the study entry criteria. Of these, 394 patients (48.9%) received AC. IPTW-adjusted Kaplan-Meier curves showed that median OS was significantly longer for AC versus observation [57.4 (interquartile range, IQR, 14.8–153.8) vs 38.2 (IQR, 10.4–125.4) months; P = 0.007]. In IPTW-adjusted Cox proportional hazards regression analysis, AC was associated with a significant OS benefit [hazard ratio (HR) = 0.73, 95% confidence interval (CI) 0.64–0.84; P
Source: Annals of Surgery - Category: Surgery Tags: ORIGINAL ARTICLES Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colorectal Cancer | Databases & Libraries | Neurology | Neurosurgery | Study | Surgery